| Name | Title | Contact Details |
|---|
Esperance Pharmaceuticals, Inc. is developing a new class of targeted oncology products that selectively kill cancer cells without harming normal cells. Targeting occurs through binding to specific receptors on the cancer cell surface. The novel product candidates destroy dividing and non-dividing cancer cells including those known to be resistant to chemotherapeutics.
Established in 1983 Southmedics Domestic Division is one of the largest independent distributors of operating room products in Canada with a dynamic and efficient sales force from coast to coast. We specialize in selling surgical and specialty operati...
Phathom Pharmaceuticals, launched in 2019 by Frazier Healthcare Partners and Takeda Pharmaceuticals, is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal (GI) diseases and disorders. The company is advancing the investigational agent vonoprazan, a novel potassium-competitive acid blocker (P-CAB). Vonoprazan has the potential to address multiple unmet needs among patients with gastroesophageal reflux disease (GERD) and other acid-related disorders.
Frontier Derm Partners is the premier dermatology clinic serving patients in Washington and Oregon
ValueOptions Inc., the nation's largest independent behavioral health care and wellness company, specializes in management for all behavioral health issues, and mental health and chemical dependency diagnoses.